uniQure N.V. (QURE) Stock Posts 30% Growth from Last Year

uniQure N.V. (NASDAQ:QURE) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The stock registered a 32.28 percent growth in the past year and a 24.84 percent year-to-date decline.

On March 11, Mizuho Securities upgraded its price target on uniQure to $35 from $12. Similarly, RBC Capital also upgraded its price target on uniQure to $35 from $11 on March 9.

uniQure Chief Executive Officer Matt Kapusta earlier expressed the company’s commitment to engaging with the FDA regarding the approval pathway for its AMT-130 for Huntington’s disease. He said:

“While we have not reached alignment with the FDA on an approval pathway, we remain confident in the strength and durability reflected in our dataset. We are committed to engaging with the FDA to define a clear and efficient path to bring this potentially transformative therapy to Huntington’s disease patients in urgent need for treatments.”

Beyond Huntington’s disease, Kapusta said the company has also made meaningful progress across its broader clinical portfolio and looks forward to additional data readouts later this year.

uniQure N.V. (NASDAQ:QURE) is a leading gene therapy company advancing transformative therapies for patients with severe medical needs such as hemophilia B. The company is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington’s disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases.

READ NEXT: 10 Best Data Center Stocks to Buy for the Long Term and 8 Must-Buy Small Cap Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.